Improve Management of heart failure with Procalcitonin - Biomarkers in Cardiology 18 (Short title: IMPACT-EU) - IMPACT-E

Thermo Fisher Scientific BRAHMS GmbH0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Patients who present to the ED with leading symptom dyspnea
•2. Suspected or known heart failure
•3. MR-proANP>300 pmol/L, BNP>350 ng/ml or NT-proBNP>1800 ng/l
•4. Patient has given written Informed Consent within study timelines to allow antibiotic treatment within 8 hours
•5. Adult patients (i.e. >18 years of age)
•6. Hospitalization for at least 1 overnight stay planned

•1. Patient participates in any other interventional clinical trial
•2. Trauma related shortness of breath
•3. Patient diagnosed with lung or thyroid cancer
•4. Known terminal disease with life expectancy of less than 6 months, e.g. advanced metastasized cancer disease
•5. Organ transplant requiring immunosuppression
•6. Abdominal, vascular or thorax surgery within the last 30 days
•7. End stage/advanced HF * defined by planned heart transplantation, or cardiogenic shock
•8. Female patients who have given birth within 3 months before study enrolment
•9. Current use of antibiotics or requirement of immediate antibiotic therapy before randomization and measurement of PCT
•10. End stage renal failure requiring dialysis
•11. Patient is not willing, or it is not possible or advisable for the patient, to follow the study schedule, including antibiotic therapy and 90 days follow up
•12. Patient has already participated in the clinical trial previously
•13. Pregnant or lactating women
•14. Patients who are institutionalized by official or judicial order
•15. Dependants of the sponsor, the CRO, the study site or the investigator

发起方

Thermo Fisher Scientific BRAHMS GmbH